scholarly journals Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jingjing Sun ◽  
Sirui Liu ◽  
Kun Fu ◽  
Ning Gao ◽  
Rui Li ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Clinical Stage ◽  
Distant Metastases ◽  
Clinicopathological Characteristics ◽  
Secretory Carcinoma ◽  
Survival Prognosis ◽  
Ki 67 ◽  
S 100 ◽  
Locoregional Recurrence Rate ◽  
Node Metastases

AbstractThis retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. In total, 13 males and 10 females (ratio, 1.3:1) aged 10 − 69 years (median, 45 years) were enrolled in this study; the average disease duration was 2.44 years (0.25–20 years). Twenty-one patients (91.3%) had SCSG in the parotid gland, and two (8.7%) in the submandibular gland. All patients had single nodules of diameters 0.8–4.8 cm (average 2.6 cm); five with lymph node metastases, and two with distant metastases. Immunohistochemically, tumors stained positive for S-100, mammaglobin, CK7, GATA3 and pan-Trk, and negative for DOG1, P63, and calponin, with Ki-67 positivity from 1 to 50%. ETV6 gene rearrangement was confirmed in 15 patients. All patients underwent oncological resection, four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one died before the last follow-up. SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.

scholarly journals Clinicopathological Characteristics and Outcomes of 23 Patients with Secretory Carcinoma of Major Salivary Glands

2021 ◽  
Author(s):  
Jingjing Sun ◽  
Sirui Liu ◽  
Kun Fu ◽  
Ning Gao ◽  
Rui Li ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Clinical Stage ◽  
Distant Metastases ◽  
Clinicopathological Characteristics ◽  
Secretory Carcinoma ◽  
Survival Prognosis ◽  
Ki 67 ◽  
S 100 ◽  
Locoregional Recurrence Rate ◽  
Node Metastases

Abstract This retrospective study investigated the clinicopathological characteristics of secretory carcinoma of salivary glands (SCSG) in 23 patients with histopathologically confirmed SCSG between January 2010 and December 2020. In total, 13 males and 10 females were enrolled (ratio, 1.3:1) from 10 to 69 years of age (median 45 y); the average disease duration was 2.44 y (0.25–20 y). Twenty-one patients (91.3%) had SCSG in the parotid gland, and two (8.7%) in the submandibular gland. All patients had single nodules with diameters of 0.8–4.8 cm (average 2.6 cm); five with lymph node metastases, and two with distant metastases. Immunohistochemically, tumors stained positive for S-100, mammaglobin, CK7, and GATA3, and negative for DOG1, P63, and calponin, with Ki-67 positivity from 1–50%. ETV6 gene rearrangement was confirmed in 15 patients. All patients underwent oncological resection, four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one died before the last follow-up. SCSGs are typically indolent, with a low locoregional recurrence rate and excellent survival. Prognosis is correlated to clinical stage, pathological grade, and surgical procedures.

scholarly journals Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands

2021 ◽  
Author(s):  
Jingjing Sun ◽  
Sirui Liu ◽  
Kun Fu ◽  
Ning Gao ◽  
Rui Li ◽  
...  
Keyword(s):  
Salivary Glands ◽  
Clinical Characteristics ◽  
Clinical Stage ◽  
Distant Metastases ◽  
Clinicopathological Characteristics ◽  
Low Grade ◽  
Secretory Carcinoma ◽  
Ki 67 ◽  
Major Salivary Glands ◽  
Salivary Gland Carcinomas

Abstract Background Secretory carcinoma of salivary glands (SCSGs) are generally low-grade salivary gland carcinomas, and are characterized by morphological resemblance to mammary analogue secretory carcinoma and ETV6–NTRK3 gene fusion. Several reports on histopathological features of SCSG have recently been published; however, little is known about the clinical characteristics of this new tumor, including its outcomes. The research is to investigate the clinicopathological characteristics of secretory carcinoma of major salivary glands and to analyze outcomes of these carcinomas as a reference for standardizing their diagnosis and treatment. Methods The cohort of this retrospective study comprised 23 patients treated for histopathologically-confirmed SCSG between January 2010 and December 2020. Their clinical characteristics and outcomes were retrieved from patient files. Results The 23 patients comprised 13 male and 10 female patients (male:female ratio 1.3:1). They were aged 10–69 years (median 45 years) and the average duration of disease was 2.44 years (0.25–20 years). Twenty-one patients (91.3%) had SCSGs in the parotid gland and two (8.7%) in the submandibular gland. All 23 patients had single nodules with diameters of 0.8–4.8 cm (average 2.6 cm). Five patients had lymph node metastases and two had distant metastases. All tumors were pathologically diagnosed as SCSGs. Immunohistochemical staining was strongly positive for S-100, mammaglobin, CK7, and Gata3, and negative for Dog1, P63 and calponin. Ki-67 positivity ranged from 1–50%. Fluorescence in situ hybridization data were available for 15 patients, in all of whom ETV6 gene rearrangement was confirmed. All patients had undergone oncological resections. Four had radioactive particles implanted postoperatively, one received chemotherapy, and seven underwent chemoradiotherapy. Six patients had regional recurrences, two distant metastases, and one had died at the time of last follow-up. Conclusions SCSGs are typically indolent with a low rate of locoregional recurrence and excellent survival. Their prognosis is correlated with clinical stage, pathological grade, and surgical procedures performed.

Immunohistochemical Expression of CD8, CDX2, P53, D2-40 and KI 67 in Colorectal Adenocarcinoma, Conventional and Malignant Colo-rectal Polyps

2018 ◽  
Vol 69 (2) ◽  
pp. 419-428
Author(s):  
Cristian Mesina ◽  
Liviu Catalin Stoean ◽  
Ruxandra Stoean ◽  
Victor Adrian Sandita ◽  
Corina Lavinia Gruia ◽  
...  
Keyword(s):  
Lymph Node ◽  
Colorectal Adenocarcinoma ◽  
Rectal Adenocarcinoma ◽  
Distant Metastases ◽  
Lymphatic Invasion ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Rectal Polyps ◽  
Node Metastases ◽  
Lymph Nodes Metastases

82 patients, who had been diagnosed with colo-rectal adenocarcinoma in our department between 2007 and 2014, were included in our study. Additionally, 31 patients with colo-rectal polyps (20 conventional adenomatous polyps and 11 malignant colo-rectal polyps) were also included in this study. The patients with colo-rectal adenocarcinoma were reevaluated in terms of gender, age, topography of recto-colic tumor, TNM stadialization, vasculo-lymphatic invasion, lymph nodes metastases and distant metastases. The study of CD8, Ki67, p53, CDX2 and D2-40 immunoexpression in colo-rectal cancer patients revealed: an elevated positivity index in patients with pT2 and pT3 stages and in patients with lymph node metastases in case of the CD8; an elevated positivity index in patients with pT2, pT3 and pT4 stage in case of Ki67; an elevated positivity index in patients with pT4 stage in in case of the p53; an increased positivity index in the pT2, pT3 stage, the absence of vasculo-lymphatic invasion, the absence of lymph node and distant metastases in case of the CDX2 and an increased positivity index in patients with the pT2, pT3 stage, the abscence of lymph node and distant metastases in case of the D2-40 Tumoral staging (pT2, pT3 and pT4) has been shown to be correlated with immunoexpression of the following markers: CD8, CDX2 and p53.

Clinicopathological Characteristics of Melanomas of the Hand

1999 ◽  
Vol 24 (4) ◽  
pp. 460-464 ◽  
Author(s):  
L. M. HOVE ◽  
L. A. AKSLEN
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Early Diagnosis ◽  
Lymph Node Metastases ◽  
Regional Lymph Node ◽  
Clinical Stage ◽  
Clinicopathological Characteristics ◽  
Local Spread ◽  
Localized Disease ◽  
Node Metastases

A 25-year clinicopathological review of 19 patients with malignant melanoma of the hand is reported. There were 11 women (median age 73 years) and eight men (median age 70 years). Eleven tumours were subungual, six on the dorsum of the hand, and two had a palmar location. Seven tumours were acral lentiginous melanomas, six were superfical spreading melanomas, and five were of the nodular subtype. Eleven patients presented with localized disease (clinical stage I), four with local spread (clinical stage II), and four with regional lymph node metastases (clinical stage III). Nine of the patients have died of the disease, with a median survival time of 30 months (range, 10–84 months). The subungual melanomas were thicker and the patients were older at presentation compared with the non-subungual sites. Review of our patients emphasized the need for early diagnosis.

scholarly journals Clinicopathological characteristics of peripheral clinical stage IA lung adenocarcinoma with high Ki-67 expression

2021 ◽  
Vol 10 (1) ◽  
pp. 152-161
Author(s):  
Zhan Liu ◽  
Hongxiang Feng ◽  
Shanwu Ma ◽  
Weipeng Shao ◽  
Jun Zhang ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Clinical Stage ◽  
Clinicopathological Characteristics ◽  
Ki 67 ◽  
Clinical Stage Ia ◽  
Stage Ia

scholarly journals Expression and clinical significance of miR-3615 in hepatocellular carcinoma

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098154
Author(s):  
Xin Yuan ◽  
Yize Zhang ◽  
Zujiang Yu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Curve ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Prognostic Information ◽  
Ki 67 ◽  
Tissue Samples ◽  
Expression Levels ◽  
Kaplan Meier ◽  
Serum Alpha Fetoprotein

Objective To investigate the association between microRNA-3615 (miR-3615) expression and the prognosis and clinicopathological features in patients with hepatocellular carcinoma (HCC). Methods We obtained clinicopathological and genomic data and prognostic information on HCC patients from The Cancer Genome Atlas (TCGA) database. We then analyzed differences in miR-3615 expression levels between HCC and adjacent tissues using SPSS software, and examined the relationships between miR-3615 expression levels and clinicopathological characteristics. We also explored the influence of miR-3615 expression levels on the prognosis of HCC patients using Kaplan–Meier survival curve analysis. Results Based on data for 345 HCC and 50 adjacent normal tissue samples, expression levels of miR-3615 were significantly higher in HCC tissues compared with adjacent tissues. MiR-3615 expression levels in HCC patients were negatively correlated with overall survival time and positively correlated with high TNM stage, serum Ki-67 expression level, and serum alpha-fetoprotein level. There were no significant correlations between miR-3615 expression and age, sex, and pathological grade. Conclusion MiR-3615 may be a promising new biomarker and prognostic factor for HCC.

Small Neuroendocrine Tumors of the Whole Gastrointestinal Tract Performed Endoscopic or Surgical Resections Also Show Positive for Lymphovascular Invasion

Digestion ◽  
2021 ◽  
pp. 1-8
Author(s):  
Haruna Miyashita ◽  
Takuji Yamasaki ◽  
Yoshihiro Akita ◽  
Yoshitaka Ando ◽  
Yuki Maruyama ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Neuroendocrine Tumors ◽  
Tumor Size ◽  
Lymphovascular Invasion ◽  
Distant Metastases ◽  
High Rate ◽  
Ki 67 ◽  
Primary Endpoints ◽  
Invasion Impact ◽  
Prognostic Stratification

<b><i>Background and Aims:</i></b> In gastrointestinal neuroendocrine tumors (GI-NETs), tumor size and grading based on cellular proliferative ability indicate biological malignancy but not necessarily clinically efficient prognostic stratification. We analyzed tumor size- and grading-based prevalence of lymphovascular invasion in GI-NETs to establish whether these are true biological malignancy indicators. <b><i>Methods:</i></b> We included 155 cases (165 lesions), diagnosed histologically with GI-NETs, that had undergone endoscopic or surgical resection. Patient age, sex, method of treatment, tumor size, invasion depth, lymphovascular invasion positivity according to Ki-67 index-based neuroendocrine tumor grading, distant metastases, and outcome were evaluated. The primary endpoints were the prevalence of lymphovascular invasion according to tumor size and grading. <b><i>Results:</i></b> Overall, 24.8% were positive for lymphovascular invasion. There was a high rate of lymphovascular invasion positivity even among grade 1 cases (22.8%). The rate of lymphovascular invasion was 3.4% for grade 1 cases &#x3c;5 mm, with a lymphovascular invasion rate of 8.7% for those 5–10 mm. Lymphovascular invasion ≤10% required a tumor size ≤8 mm, and lymphovascular invasion ≤5% required a tumor size ≤6 mm. A cutoff of 6 mm was identified, which yielded a sensitivity of 79% and a specificity of 63%. Even small GI-NETs grade 1 of the whole GI tract also showed positive for lymphovascular invasion. <b><i>Conclusions:</i></b> GI-NETs ≤10 mm had a lymphovascular invasion prevalence exceeding 10%. The lymphovascular invasion impact in GI-NET development is incompletely understood, but careful follow-up, including consideration of additional surgical resection, is crucial in cases with lymphovascular invasion.

scholarly journals Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Kosei Takagi ◽  
Yuzo Umeda ◽  
Ryuichi Yoshida ◽  
Kazuhiro Yoshida ◽  
Kazuya Yasui ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neuroendocrine Tumor ◽  
Lymph Node Metastases ◽  
Treatment Strategy ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Ki 67 ◽  
Invasive Approach ◽  
Robotic Pancreatoduodenectomy ◽  
Estimated Blood Loss ◽  
Node Metastases

Abstract Background Contrary to the increasing incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), GEP-NETs of the accessory papilla of the duodenum are extremely rare. Furthermore, there have been no recommendations regarding the treatment strategy for GEP-NETs of the accessory papilla of the duodenum. We present a case of GEP-NET of the accessory papilla of the duodenum successfully treated with robotic pancreatoduodenectomy. Case presentation A case of a 70-year-old complaining of no symptoms was diagnosed with GEP-NET of the accessory papilla of the duodenum. A 8-mm tumor was located at the submucosal layer with a biopsy demonstrating a neuroendocrine tumor grade 1. The patient underwent robotic pancreatoduodenectomy as curative resection for the tumor. The total operative time was 406 min with an estimated blood loss of 150 mL. The histological examination revealed a well-differentiated neuroendocrine tumor with low Ki-67 index (< 1%). In the posterior areas of the pancreas, the lymph node metastases were detected. The patient was followed up for 6 months with no recurrence postoperatively. Conclusions Considering the potential risks of the lymph node metastases, the standard treatment strategy for GEP-NETs of the accessory papilla of the duodenum should be radical resection with pancreatoduodenectomy. Minimally invasive approach can be the alternative to the conventional open surgery.

Sign in / Sign up

Export Citation Format

Share Document